Suppression of tumor cell growth by p53 results from the activation of both apoptosis and cell cycle arrest functions that have been shown to be separable activities of p53. We report here that some mutants in the p53 hinge domain, a short linker between the DNA binding and tetramerization domains, differentially activated the promoters of p53 target genes and possessed an impaired apoptotic function. Our results indicate that the hinge domain may play an important role in differentially regulating p53 cell cycle arrest and apoptotic functions. However, the mechanisms by which p53 hinge domain mutants differentially activate its target genes, e.g. p21 WAF1/CIP1 and Bax, remain unknown. To investigate the possible mechanisms, recombinant p21
Suppression of tumor cell growth by p53 results from the activation of both apoptosis and cell cycle arrest functions that have been shown to be separable activities of p53. We report here that some mutants in the p53 hinge domain, a short linker between the DNA binding and tetramerization domains, differentially activated the promoters of p53 target genes and possessed an impaired apoptotic function. Our results indicate that the hinge domain may play an important role in differentially regulating p53 cell cycle arrest and apoptotic functions. However, the mechanisms by which p53 hinge domain mutants differentially activate its target genes, e.g. p21 WAF1/CIP1 and Bax, remain unknown. To investigate the possible mechanisms, recombinant p21
WAF1/CIP1
and Bax promoters were constructed, resulting in rearrangement of the existing p53 binding sites within a given promoter or actually swapping p53 binding sites between the two promoters. Our results suggest that multiple mechanisms of differential transactivation occur, depending on the molecular nature of the relevant hinge domain mutant, such as the possibility that dual separate DNA binding sites in the p21 WAF1/CIP1 promoter are responsible for the selective transactivation activity of p53 hinge domain mutant del300 -327, which has a large deletion in the hinge domain. Lack of ideal p53 binding sites in the Bax promoter results in less potent activation than that seen with the p21 WAF1/CIP1 promoter when it is transactivated by hinge domain point mutant mutR306P or short deletion mutant del300 -308 proteins. How the single mutation or the short deletion affect the conformation of p53 and consequently the transactivation of the Bax promoter will require further investigation of the relevant p53 protein: DNA-binding domain by NMR and x-ray crystallographic techniques.
p53 is the most commonly mutated tumor suppressor gene in human cancers (1) . Although there is no clear essential role for p53 during normal development, lack of functional p53 is associated with an increased risk of tumor development, both in mice with heterozygous or homozygous p53 deletions and in humans carrying a germline p53 mutation (2) (3) (4) (5) . Two important activities of p53 that contribute to the inhibition of tumor growth have been described: the ability to activate cell cycle arrest and the ability to induce apoptosis (6) .
The cell cycle arrest is mediated, at least in part, by the induction by p53 of p21 WAF1/CIP1 (7) , an inhibitor of the cyclindependent kinases that are necessary for progression through the cell cycle (8, 9) . The contribution of sequence-specific transcriptional activation to the induction of apoptosis is less clear. However, several p53-inducible genes with a clear potential for contribution to apoptosis, such as Bax, Fas/apop1, KILLER/ DR5, PIG3, and IGF-BP3 have been reported (10 -14) .
Cell cycle arrest and apoptosis induced by wild type p53 appear to be differently regulated functions. Some tumor-derived p53 point mutants within the sequence-specific DNAbinding domain show specific loss of apoptotic function despite retaining wild type cell cycle arrest activities (15) (16) (17) . Other mutants, which are unable to induce a cell cycle arrest, remain competent for the induction of apoptosis in some cells (18) .
We have previously reported that two germline-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions (19, 20) . The hinge domain is a small short linker between the specific DNA-binding domain and the tetramerization domain. Other investigators demonstrated that a mutant p53 with a deleted hinge domain exhibited novel DNA binding properties consistent with an inability to recognize four contiguous DNA repeats of a p53 consensus binding site, suggesting that this domain may be involved in allosteric regulation of DNA binding (21) . To futher elucidate the biological functions of the p53 hinge domain, we investigated additional p53 hinge domain mutants with sporadic point mutations and deletions within this domain to determine whether they have impaired functions. We found that certain p53 hinge domain mutants differentially activated the promoters of p53 target genes p21 WAF1/CIP1 and Bax and possessed an impaired apoptotic function. To understand the possible mechanisms by which the hinge domain mutants selectively use the promoters of p53 target genes, we swapped the p53 binding sites between the promoters of p21 WAF1/CIP1 and Bax and further rearranged the p53 binding sites in the p21 WAF1/CIP1 promoter to observe whether the transactivation activities of the hinge domain mutants would alter accordingly.
EXPERIMENTAL PROCEDURES

Plasmids
Plasmids pGEMhp53wtB, pGEMhp53del300-308, pGEMhp53del300-327, and pGEMhp53del324-332 were generous gifts from T. D. Halazonetis (Wistar Institute, Philadelphia, PA). The mutations P300S and R306P and the deletion at residues 324 -325 were introduced into the context of pGEMhp53wtB by site-directed mutagenesis as described previously (19) . These constructs are termed pGEMhp53mutP300S, pGEMhp53mutR306P, and pGEMhp53del324-325, respectively. The wild type and various mutant p53 inserts from the above corresponding PGEM4 plasmids were subcloned into the PvuII and HindIII sites of the pREP4 (Invitrogen), a Rous sarcoma virus promoter-driven expression vector with an episomal origin of replication. A DNA-binding domain mutant, mutV143A, was used as a negative control in this study. It lacks all transactivating and apoptosis-inducing functions that were analyzed in this study (19) .
Cell Culture
The p53-null human tumor cell line Saos-2 was obtained from Dr. W. H. Lee (University of Texas, San Antonio, TX) and was maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.
Transcriptional Regulation Activity and Protein Analysis
Two firefly luciferase reporter constructs, the p21 WAF1/CIP1 promoter (WWP-luc) and the Bax promoter (Bax-luc) were gifts from Drs. B. Vogelstein (The Johns Hopkins University, Baltimore, MD) and J. C. Reed (The Burnham Institute, La Jolla, CA), respectively. Saos-2 cells (2.0 ϫ 10 5 ) were seeded into each well of a 6-well plate. The following day, 1 g of either WWP-luc or Bax-luc was cotransfected with 0.2 g of a p53-expressing plasmid and 0.02 g of a Renilla luciferase internal control plasmid, pCMV-RL (Promega), using the Effectene procedure according to the manufacturer's protocol (Qiagen, Germany). Each transfection of the different p53 expression plasmids was done in duplicate for each experiment, and the experiment was repeated three to four times with the indicated wild type or mutant p53. The cell lysates were prepared 24 h post-transfection for luciferase assays. The ratio of firefly to Renilla luciferase was calculated for each transfection, and the results were expressed as the fold transactivation relative to wild type p53 averaged over the set of the experiments.
Western blotting was performed as described previously (19, 20) . Equal amounts (15 g) of cell lysates were subjected to polyacrylamide gel electrophoresis and then were transferred to an Immobilon polyvinylidene difluoride membrane (Millipore). The proteins were detected with human p53 monoclonal mouse antibody DO-1 (1:500 dilution; Santa Cruz), p21 WAF1/CIP1 polyclonal rabbit antibody C-19 (1:300; Santa Cruz), and monoclonal mouse anti-␤-actin antibody (1:5000; Sigma). Secondary antibodies were either anti-mouse Ig conjugated to horseradish peroxidase or anti-rabbit-Ig conjugated to horseradish peroxidase (both antibodies at 1:10,000 dilution; Santa Cruz).
Growth Suppression Assay
Saos-2 cells (2.0 ϫ 10 5 ) were seeded into each well of a 6-well plate. The next day, cells were transfected with 1 g of the indicated p53 wild type or mutant expression plasmids. The cells were placed under hygromycin selection (100 units/ml) 48 h post-transfection. After 12-14 days of selection, hygromycin-resistant colonies were fixed and stained with 0.3% crystal violet in ethanol, and the colonies were counted.
Fluorescence-activated Cell Sorting Analysis
The day before transfection, 7.5 ϫ 10 5 cells were seeded into a 100-mm-diameter Petri dish. The cells were transfected with 2 g of each p53 expression plasmid the next day. Total populations of transfected cells, including floating and adherent cells, were harvested at the indicated times and fixed in 75% ethanol for at least 2 h at Ϫ20°C. The cells were then rehydrated in cold phosphate-buffered saline, pelleted and incubated with 20 l (for 1 ϫ 10 6 cells) fluorescein isothiocyanateconjugated p53 antibody (Pharmagen) overnight at 4°C in the dark. Following phosphate-buffered saline washes, the cells were treated with 150 g/ml RNase A for 30 min at 37°C and stained with 1 g/ml propidium iodide for 15 min. The cells were analyzed in a FACScan cell scanner (Becton Dickinson) for their fluorescein isothiocyanate intensity (green channel) and propidium iodide intensity (red channel). Total populations were gated to remove doublets and very small debris. Background levels of fluorescein isothiocyanate fluorescence were established with the untransfected cells. The cells in p53 transfected populations with high fluorescence were gated and analyzed as the p53-expressing population. Apoptosis analysis was performed with the CellQuest analysis software (Becton Dickinson). Apoptosis induced by each p53 protein was expressed as the percentage of the cells with a sub-G 1 DNA content in excess of that seen in the vector-only transfected population. (22) , whereas the Bax promoter contains a single p53 binding site (BaxBS) (10) . The consensus p53 BSs were swapped between WWP-luc and Bax-luc by using a three-step polymerase chain reaction mutagenesis procedure (23 WAF1/CIP1 promoter) (see Table I and Fig. 1A ). The plasmid constructs in which p21BSs replace BaxBS within the Bax core promoter reporter (Bax-luc) were named Bax(p21BS)-lucs. They included Bax(p21BS1)-luc, Bax(p21BS2)-luc, Bax(p21BS1/BS2)-luc (there are no nucleotides between the two binding sites), and Bax(p21BS1ϩBS2)-luc (between the two binding sites, there are 870 bp of intervening DNA sequence retained from the p21 WAF1/CIP1 promoter) (see Table I and Fig. 1B) .
The
Rearrangement of the p53 Binding Sites in the p21 WAF1/CIP1 Promoter-By using the three-step polymerase chain reaction mutagenesis protocol (23), BS1 and BS2 were individually removed from the p21 WAF1/CIP1 promoter reporter, WWP-luc, forming the new plasmid constructs WWP(p21BS2)-luc and WWP(p21BS1)-luc, respectively. The WWP(p21BS1/BS2)-luc was constructed by eliminating the intervening nucleotides between BS1 and BS2 in the WWP-luc (see Table I and Fig. 1C ).
RESULTS
Differential Transcriptional Activities of p53 Hinge Domain
Mutants-The hinge domain is a short linker that links the p53 DNA-binding domain (spanning amino acids 102-297) to the tetramerization domain (encompassing amino acids 326 -354) (24, 25) . Thus, the hinge domain is positioned between amino acids 298 and 325 (19) . Six p53 hinge domain mutants were analyzed for their ability to activate transcription from two important p53-responsive promoters, p21 WAF1/CIP1 and Bax, in this study. The mutants included two spontaneous point mutation (mutP300S, mutR306P) and four deletion mutants. Two of these four deletion mutants have deleted amino acids from only the hinge domain (del324 -325 and del300 -308), and the other two also lack two or more amino acids from the tetramerization domain, in addition to the hinge domain (del300 -327 and del324 -332). Also included in this study was mutV143A, a well studied p53 missense mutant with a mutation at codon 143 within the p53-specific DNA-binding domain. This mutant has no ability to induce either cell cycle arrest or apoptosis at 37°C (19, 26) .
Analysis of the mutants for the ability to transactivate the p21 WAF1/CIP1 promoter in the p53 null human Saos-2 cell line showed that almost all of the hinge domain mutants retained their ability to transactivate the p21 WAF1/CIP1 promoter to a level comparable with or even higher than that exhibited by wild type p53 protein ( Fig. 2A) . Only one mutant, del324 -332, which has two amino acids (amino acids 324 and 325) from the hinge domain and seven amino acids (amino acids 326 -332) from the tetramerization domain deleted, was unable to transactivate the p21 WAF1/CIP1 promoter ( Fig. 2A) . Because the mutant del324 -325 retained the ability to transactivate the p21 WAF1/CIP1 promoter, we assume that the defect in the transactivation of the p21 WAF1/CIP1 promoter by del324 -332 was most likely due to its deletion of amino acids 326 -332 within the tetramerization domain. Thus, del324 -332 is considered to be a tetramerization domain mutant. This tetramerization domain mutant has lost all transactivation, growth suppression, and apoptosis-inducing functions (data not shown), similar to muta143v, and was not analyzed further in this paper. Consistent with the observation from transcriptional activation of the p21 WAF1/CIP1 promoter, endogenous p21 WAF1/CIP1 protein expression was activated by all of the hinge domain mutants to levels comparable with that of the wild type p53 protein (Fig.  2B) . In contrast to the transactivation of the p21 WAF1/CIP1 1 The abbreviations used are: bp, base pair(s); FACS, fluorescenceactivated cell sorting; BS, binding site.
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promoter, three hinge domain mutants (mutR306P, del300 -308, and del300 -327) were partly defective in activating the transcription from the Bax promoter (Fig. 2C) . They displayed an average transactivation of 26, 30, and 24% of wild type p53, respectively. By contrast, the mutants, mutP300S and del324 -325 retained the wild type ability to transactivate the Bax promoter.
No Suppression of Saos-2 Cell Growth by Hinge Domain Mutants-To investigate whether the hinge domain mutants that retained the ability to transactivate the p21 WAF1/CIP1 promoter could induce an overall arrest of cell growth, we performed growth suppression assays with p53-transfected Saos-2 cells. Expression vectors for the various p53 cDNAs bearing a hygromycin resistance gene were transfected into Saos-2 cells. After ϳ2 weeks of selection in medium containing hygromycin, the vector control transfection yielded an average of 145 colonies (this experiment was repeated three times, with each experiment done in duplicate). Consistent with the transcriptional activation of p21 WAF1/CIP1 promoters, the hinge domain mutants retained all of the growth-suppressing activity of wild type p53 (Fig. 3) .
Impaired promoter (p21BSs) were swapped into the Bax promoter to replace the binding site (BaxBS). The following novel constructs were generated: Bax(p21BS1)-luc, Bax-(p21BS2)-luc, Bax(p21BS1ϩp21BS2)-luc, and Bax (p21BS1/BS2)-luc (intervening 870 bp between the two sites were deleted). C, rearrangement of the p53 binding sites within the p21 WAF1/CIP1 promoter. BS1 or BS2 was removed, or the 870-bp spacer between the two binding sites was deleted. The name of each recombinant reporter construct is written as "core promoter (p53 consensus binding sites)-luciferase." Luc, luciferase. *, here the BaxBS1 and BaxBS2 are the same BaxBS consensus sequence but located in the different positions, e.g. the positions of p21BS1 and p21BS2 separately, whereas p21BS1 and p21BS2 are separate and distinct consensus sequences.
p53 Hinge Domain Mutants with Impaired Apoptotic Functionapoptosis, and our previous (19) and current studies have demonstrated that some hinge domain mutants have reduced the ability to transactivate the Bax promoter, we therefore sought to test their ability to induce apoptosis in Saos-2 cells. Various p53 wild type or mutant expression plasmids were transfected into Saos-2 cells. The samples were fixed 48 and 72 h posttransfection. The cells were then subjected to FACS analysis. We found that the mutants (mutR306P, del300 -308, and del300 -327) that had a reduced ability to transactivate the Bax promoter exhibited more than 50% loss of apoptosis induction compared with wild type p53. mutP300S and del324 -325 induced the same level of apoptosis as wild type p53, and mutV143A had very little apoptotic function (Fig. 4, A and B) . In agreement with our earlier report (19) , more Saos-2 cells had undergone apoptosis at 72 h than 48 h post-transfection (Fig. 4,  A and B) . Examples of the FACS analyses are shown in Fig. 4C . WAF1/CIP1 and Bax luciferase reporter plasmids were cotransfected with wild type p53 and the Renilla luciferase internal control, pCMV-RL (Promega) into Saos-2 cells. Twenty-four hours post-transfection, the cell lysates were prepared, and the luciferase activities were measured with a luminometer. The results were expressed as the percentages of transactivation relative to the original WWP-luc or Bax-luc reporter. Substituting BaxBS within Bax-luc with p21BS1 or p21BS2, as well as p21BS1/BS2 or p21(BS1ϩBS2), increased the transcriptional activities by 5-10-fold compared with Bax-luc and 1.5-3-fold compared with WWP-luc (Fig. 5A) . The transactivation levels of Bax(p21BS1)- , p53, and ␤-actin antibodies separately. The figure displayed is representative of four independent experiments. C, the reporter plasmid Bax-luc, which contains the Bax promoter ligated to the firefly luciferase coding region, was cotransfected with an expression plasmid containing the indicated p53 cDNA into Saos-2 cells. Each value represents the average of three independent experiments. No error bar means that the standard deviation is less than 1. luc and Bax(p21BS2)-luc are almost same, demonstrating that these two binding sites have similar affinities for p53 binding, although the p21BS2 is less ideal than p21BS1 (Table I) according to the definition of an optimal p53 BS (27) . These data suggest that the idealness of a binding site is not the only factor that affects the affinity for the wild type p53 binding. Inserting the BaxBS into the p21 WAF1/CIP1 promoter significantly diminished the transcriptional activities (Fig. 5B) , which, together with the data shown in Fig. 5A , supports the notion that the p21BS has a stronger affinity than the BaxBS (28). Replacing p21BS1 with BaxBS but retaining p21BS2 in the p21
promoter (WWP(BaxBSϩp21BS2)-luc) had little effect on the transcriptional activity. However, replacing the p21BS2 with the BaxBS while retaining p21BS1 (WWP(p21BS1ϩBaxBS)-luc) showed an approximately 80% decrease in comparison with WWP-luc (Fig. 5B) . Compared with WWP-luc, WWP-(p21BS1)-luc and WWP(p21BS2)-luc showed significantly reduced luciferase activities (Fig. 5C ). Retaining p21BS1 in the p21 WAF1/CIP1 promoter (WWP(p21BS1)-luc) resulted in lower luciferase activity than retaining p21BS2 (WWP(p21BS2)-luc). The data of Fig. 5 (B and C) suggest that the p21BS2 position in WWP-luc, which is closer to the TATA box of the p21
promoter, might be the dominant site in response to p53 transactivation. Deleting the intervening nucleotides between these 
two binding sites (WWP(p21BS1/BS2)-luc) did not significantly affect the transcriptional activity compared with WWP-luc. (Fig.  5C ), indicating that the intervening sequence does not significantly affect the p21 WAF1/CIP1 promoter activation activity.
Transactivation of the p53 BS Swapped p21 WAF1/CIP1 and Bax Promoter Reporters by Wild Type p53 and Various p53
Hinge Domain Mutant Plasmids-Wild type p53 more efficiently transactivated the p21 WAF1/CIP1 promoter compared with the Bax promoter (Fig. 5, A and B) . Other groups have speculated that this is due to the fact that p53 binds more efficiently to the binding sites in the p21 WAF1/CIP1 promoter than in the Bax promoter (28) . To investigate whether this is the mechanism by which the p53 hinge domain mutants differentially transactivated the p21 WAF1/CIP1 and Bax promoters, we swapped the consensus p53 BSs between the p21 WAF1/CIP1
and Bax promoters.
The p21BS-inserted Bax promoter plasmids, including Bax(p21BS1)-luc, Bax(p21BS2)-luc, Bax(p21BS1/BS2)-luc, and Bax(p21BS1ϩBS2)-luc (Table I) , were cotransfected with wild type p53 and the various p53 mutants. Of the three hinge domain mutants that had defects in transactivating the Baxluc (Fig. 2C ), mutR306P and del300 -308 had almost the same Table I . 
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ability to activate the transcriptions from Bax(p21BS1)-luc, Bax(p21BS1/BS2-luc), and Bax(p21BS1ϩBS2)-luc as wild type p53 (Fig. 6 , A, C, and D), whereas they showed a 25-30% reduction in the ability to transactivate Bax(p21BS2)-luc (Fig.  6B) . These results suggest that the unidealness of a binding site (BaxBS or p21BS2) in a promoter may reduce the transactivation of the promoter by these two hinge domain mutation. Unlike mutR306P and del300 -308, the del300 -327 mutant showed about 50 -80% reduction in the ability to transactivate Bax(p21BS1)-luc, Bax(p21BS2)-luc, and Baxp21BS1/BS2-luc (Fig. 6, A-C) . This indicates that a single p53 binding site or two binding sites without a spacer may greatly reduce the transcriptional responsiveness to this p53 hinge domain deletion mutant and therefore explains why the del300 -327 mutant had a decreased ability to transactivate the Bax promoter. The transactivation level of this mutant was restored when cotransfected with Bax(p21BS1ϩBS2)-luc (Fig. 6D) . We speculate that the spacer between the two binding sites helps to restore its ability to transactivate the recombinant promoter. Recombinant WWP(BaxBS)-luc plasmids, which were made by inserting BaxBS into the p21 WAF1/CIP1 promoter reporter, including WWP(BaxBS1)-luc, WWP(BaxBS2)-luc, WWP(BaxBSϩBaxBS)-luc, WWP(BaxBSϩp21BS2)-luc, and WWP(p21BS1ϩBaxBS)-luc (Table I) , were cotransfected with wild type p53 and the various p53 mutants. Transactivation of the WWP(BaxBS1)-luc and WWP(BaxBS2)-luc plasmids by wild type p53 was very weak (Fig. 5B) , and no significant differences among p53 wild type, mutants, and vector control were observed (data not shown). The reason that the same BaxBS became much less responsive to p53 when it was placed in the positions of the p21BSs in WWP-luc (WWP(BaxBS1)-luc and WWP(BaxBS2)-luc) than it was in the Baxluc (Fig. 5B) is probably because the BaxBS position in Baxluc is much closer to the TATA box (10) compared with the p21BS position in WWP-luc (7) .
Of the three hinge domain mutants that retained the wild type p53 ability to transactivate WWP-luc, two (mutR306P and del300 -308) showed about 35% reduction, and one (del300 -327) retained its ability to transactivate the WWP(BaxBSϩBaxBS)-luc plasmids compared with wide type p53 (Fig. 7A) . This supports our speculation that two or more binding sites in the p21 WAF1/CIP1 promoter with a spacer between them could rescue the transactivation activity of del300 -327. Retaining either p21BS1 or p21BS2 increased the transactivation levels of mutR306P and del300 -308 to that of wild type p53 (Fig. 7, B and  C) , further indicating that the transactivation activity of these two mutants is mainly affected by the affinity of the respective binding sites for p53 protein.
Transactivation of the p53 BS-rearranged p21 WAF1/CIP1
Promoters by Wild Type p53 and the Hinge Domain Mutants-To further determine whether the reduced transactivation of the Bax(p21BS1)-luc, Bax(p21BS2)-luc, and Bax(p21BS1/BS2)-luc reporters by del300 -327 (Fig. 7, A-C) is due to the promoter having only a single binding site or two binding sites without a p53 Hinge Domain Mutants with Impaired Apoptotic Functionspacer, we rearranged WWP-luc by reducing the number of binding sites in it or removing the intervening DNA sequence between the binding sites. The rearranged p21 WAF1/CIP1 promoter reporters, including WWP(p21BS1)-luc, WWP(p21BS2)-luc, and WWP(p21BS1/BS2)-luc (Table I) , were cotransfected with the wild type and various mutant p53 plasmids. Unexpectedly, del300 -327 did not show a reduced transactivation of these three recombinant plasmids; instead, it exhibited the same level of transactivation activity as wild type p53. Another two mutants, mutR306P and del300 -308, showed 20 -25% reduction in transactivation of WWP(p21BS2)-luc (Fig. 8) . The reduction is very close to the decrease in the transactivation of the Bax (p21BS2)-luc (Fig. 6B) , suggesting that p21BS2 has a reduced affinity for binding these two mutants.
DISCUSSION
In this study we found that one sporadic missense mutation and two deletion mutants in the hinge domain had defects in transactivation of the Bax promoter and, correspondingly, a clear impaired apoptotic function but retained the wild type ability to transactivate the p21 WAF1/CIP1 promoter and to suppress cell growth.
Several studies have demonstrated that tumor-derived p53 point mutants have differential specificity with respect to their ability to activate different p53 promoters (15) (16) (17) . The amino acid substitutions carried by these mutants are in the DNAbinding domain of p53, and their transcriptional activities correlated with their abilities to bind DNA containing the consensus p53 binding site present in each of the promoters. The hinge domain of the p53 molecule (residues 298 -325) lies between the sequence-specific DNA-binding domain and the tetramerization domain. We speculated that the hinge domain must remain flexible for proper alignment of the tetramerization motifs (residues 326 -354) of individual p53 polypeptides, based on two studies of both the core sequence-specific DNAbinding domain and the tetramerization domain (24, 25) . Mutations or deletions that affect the flexibility of the hinge domain may have adverse effects on the conformational changes that the p53 tetramer is hypothesized to undergo on DNA binding and thus may hinder the efficiency of binding of the p53 tetramer to the p53 consensus binding site within p53-responsive promoters, e.g. p21 WAF1/CIP1 and Bax. Futhermore, our previous and present studies show that some mutation or deletion mutants in the DNA hinge domain exhibited a differential ability to transactivate p53-responsive promoters (19, 20) . The fact that the hinge domain mutants share this property with certain p53 mutations in the specific DNA-binding domain (15) (16) (17) 26) indicates that the hinge domain may be involved in regulation of the DNA binding activity of p53 in vivo. Nevertheless, how p53 mutants, including hinge domain mutants, differentially transactivate downstream gene promoters remains unknown. Some studies suggested that the extent of the damage to the p53 domain involved in its DNA 
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binding property is one of the reasons for the selective activation of target gene promoters (29) . In this model, the speculation is that if the DNA binding property is moderately damaged, the promoters with a low affinity for p53 binding will be those most likely to lose their responsiveness to p53 transactivation. When the p53 domain responsible for its binding property is severely damaged, none of the promoters, no matter whether they possess a high or a low affinity for p53, will be responsive to p53 transactivation. This model accommodates certain of the p53 hinge domain mutants that retain p21 WAF1/ CIP1 transactivation but lose the ability to transactivate the Bax promoter and induce apoptosis, although whether and how the DNA binding property of these mutants is damaged remains unclear. This model relies on the observation that the Bax promoter has a lower affinity for p53 compared with other p53-responsive promoters such as p21 WAF1/CIP1 (28) . One possible explanation for the weaker binding by p53 to the Bax promoter is that the Bax promoter does not contain an ideal consensus p53 binding element, i.e. two adjacent 10-bp consensus sites containing four contiguous pentanucleotide repeats (27) . Rather, this site contains a single perfect 10-bp consensus site flanked on the 5Ј side by one and on the 3Ј side by two imperfect 10-bp motifs (10) . However, this model is not consistent with the observation in this study that the mutant del300 -327, which has an aberrant DNA binding property (21) , exhibited the same ability as wild type p53 to transactivate the imperfect consensus BaxBS within the WWP-luc reporter (Fig.  7A) but displayed a significant reduction in the transactivation of the ideal p21BSs in the Bax-luc reporters (Fig. 6, A-C) . Thus, we speculate that some other factors, in addition to the optimal p53 binding sites may play a key role in the differential activation of the p21 WAF1/CIP1 and Bax promoters by p53 hinge domain mutants.
The hinge domain is a linker between the specific DNA binding and tetramerization domains (19) . Deletion of this intervening stretch of DNA in mutant del300 -327 may restrict the ability of the p53 binding domains to align with contiguous pentanucleotides. In this case, even though the p21 WAF1/CIP1 or Bax promoter contains a perfect consensus p53 binding site, lack of the linker prevents the dihedral symmetry of the mutant p53 tetramer. Thus, not all of the four DNA-binding domains would be able to make contact with the binding site (Fig.  9, A-C) . However, there are two binding sites present in the p21 WAF1/CIP1 promoter, and, moreover, there is a significant distance between them (22) . The presence of the dual, separated consensus binding sites allows for the possibility that the del300 -327 mutant tetramer is able to bind to four pentanucleotide repeats that span two consensus binding sites (Fig. 9D) through forming a DNA loop between the two binding sites (30) . Thus, the mutant may compensate for the defect because of the lacked linker and retain the ability to transactivate the p21 WAF1/CIP1 promoter (Fig. 6D) . To further test this model, we deleted one of the two p53 binding sites within p21
promoter, as well as removing the intervening nucleotides between the two binding sites. The transactivation results (Fig. 8) were not consistent with the model because the reduction in the p53 Hinge Domain Mutants with Impaired Apoptotic Functionnumber of the p53 binding sites in the p21 WAF1/CIP1 promoter did not result in a reduction of the transactivation activity of del300 -327. This finding indicates that there might be a third p53 binding site present in the p21 WAF1/CIP1 promoter. This putative third binding site would have to have a weak affinity for p53 binding because the negative control (WWP-NO-BS) lacking either BS1 or BS2 in the p21 promoter resulted in very weak promoter activity (Fig. 5C) . Moreover, this putative third weak binding site may not be between BS1 and BS2 of the p21 promoter because elimination of the intervening nucleotides between the two binding sites had little effect on the transactivation activity of the wild type p53 (Fig. 5A) . Alternatively, some region of the flanking sequences around the binding sites in the p21 WAF1/CIP1 promoter may play a role in maintaining the responsiveness to p53 binding.
In this study, we also observed that the mutants mutR306P and del300 -308 had a reduced ability to transactivate Bax-luc, WWP(BaxBSϩBaxBS)-luc, Bax(p21BS2)-luc, and WWP(p21BS2)-luc compared with WWP-luc, indicating that the transactivation by these two mutants is partly affected by the idealness of the consensus p53 binding sites. How the single mutation at codon 306 or the short deletion that includes this codon affects the conformation of p53 and consequently the transactivation of the Bax promoter will require further investigation of the relevant p53 protein: DNA-binding domain by NMR and x-ray crystallographic techniques.
In summary, our study demonstrates that some p53 hinge domain mutants exhibit a differential transactivation of p53 target cellular promoters. They retain cell growth arrest but lose apoptotic functions. One of the mechanisms by which some of the hinge domain deletion mutants selectively transactivate p21 WAF1/CIP1 is that the presence of dual, separated consensus p53 binding sites in the p21 WAF1/CIP1 promoter compensates for the defect of the hinge domain and restores the ability to transactivate the p21 WAF1/CIP1 , but not the Bax promoter, which has only a single binding site. Why the hinge domain point mutation mutant (mutR306P) and the short deletion mutant (del300 -308) showed differential transactivation activity remains unknown. Our results clearly indicate that the hinge domain is important for maintaining the p53 normal apoptotic functions and also support the notion that cell cycle arrest and apoptotic functions are differentially regulated by p53. Several of the hinge domain point mutants examined in the earlier studies (19, 20) were identical to documented Li-Fraumeni germ-line mutations, further underscoring the physiological importance of the hinge domain for p53 function. 
